Podcast Index
Parcourez les podcasts par catégorie, ouvrez les épisodes récents et téléchargez l’audio pour l’écouter hors ligne.
BioCentury This Week
BioCentury
Grow My Salon Business Podcast
Antony Whitaker
Financially Confident Christian
Ralph V. Estep, Jr.
Growth Now Movement with Justin Schenck
Justin Schenck
Optimal Finance Daily - Financial Independence and Money Advice
Optimal Living Daily | Diania Merriam
Wholesaling Inc with Brent Daniels
Find distressed properties for pennies on the dollar and turn them for huge profits!
The Bitcoin Standard Podcast
Dr. Saifedean Ammous
The Startup CPG Podcast
Startup CPG
Business with Beers
Brian Beers
Elite Business Advice Podcast
Elite Business Advisors
Bondcast - The Rates Podcast
NatWest Corporates and Institutions
Earthlings 2.0 Podcast
Lisa Ann Pinkerton
The Clinic Marketing Podcast | Local SEO & Healthcare Online Marketing Tips for Clinic Owners & Wellness Providers
Darcy Sullivan, Online Marketing Strategist & SEO Expert // Propel Marketing & Design
Economia do Futuro
Melina Costa
Radical Disruption
Mya Nichol
Managing Made Simple
Lia Garvin
The Business Savvy Therapist: Marketing, Hiring & Systems to Grow and Scale Your Therapy Practice
Nicole McCance
Seven Figure Standard
Arash Vossoughi and Mykie Stiller
Do This, NOT That: Marketing Tips with Jay Schwedelson
GURU Media Hub
Founders Podcast
Ash Lonare
Wantrepreneur to Entrepreneur | Start and Grow Your Own Business
Brian Lofrumento
Hamza Selfimprovement
Adonis Gang
The Strategic Entrepreneur with Cindy Gordon
Cindy Gordon, Selective Visibility Strategist, Exclusively Cindy
Midlife Advice | Perimenopause, Hormones and Midlife Women’s Health
Jessica Long | Helping Overwhelmed Women Over 40 Feel Fully Alive Again
Organized Money
Rock Creek Sound
The RAL Room Assisted Living Podcast
Charlie Cameron and Dr. Alex Schloe
Ecosysteming
NC IDEA
FIVP Practice Matters
FIVP Practice Matters
Factory of the Future Podcast
AW Schultz & Alexandria Burek
Simply Accounts & Tax's Podcast
Simon Sturman
In the Money with Amber Kanwar
Amber Kanwar
Second Home First
Second Home First
Rental Income Podcast With Dan Lane
Rental Income Podcast
The Reluctant Entrepreneur Podcast
Mike Konrad
Life Kit: Money
NPR
Jimmy Talks Construction
James Starbuck
Upmarket: The Business of Real Estate Photography & Media
Upmarket Studios
Business
BioCentury
New Parkinson’s disease programs aim to move beyond the historical norm of symptom management, branching into targeted therapeutics and cell therapies. On the latest BioCentury This Week podcast, BioCentury’s analysts re...
AbbVie's $10.9 billion deal to acquire Apogee will expand its immunology pipeline by delivering assets for atopic dermatitis and asthma. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the takeo...
Biotech IPOs that are getting out remain hot — but will that continue into the fall? On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the market for fresh biotech paper on NASDAQ, including the $...
Getting into the clinic fast to de-risk assets has become the name of the game in biotech, and at the academia-industry interface, too.From AI to NAMs to starting a Phase I trial in the U.S., BioCentury’s 3rd Grand Round...
FDA’s new leadership is sailing the agency into calmer waters amid a search for a permanent commissioner and permanent center directors. On the latest BioCentury This Week podcast, BioCentury Washington Editor Steve Usdi...
Revolution Medicines continues to impress with more pancreatic cancer data, earning a standing ovation at ASCO over the weekend. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the detailed data...
At ASCO among presentations focused on pancreatic cancer innovation beyond KRAS; however, abstracts for the cancer conference also highlight ADCs, bispecifics and diagnostics that are broadening the field’s approach to t...
Marty Makary wasn’t the only official on the outs at FDA last week in another tumultuous turn of events for the regulatory agency. On the latest BioCentury This Week podcast, BioCentury Washington Editor Steve Usdin disc...
China’s speed in generating first-in-human data has catalyzed a race across the globe to reshape regulatory requirements to compete. BioCentury’s analysts, along with special guests Detlev Mennerich, head of Boehringer I...
Marty Makary’s hold on the top job at FDA is slipping, with White House leaks about President Donald Trump’s displeasure with the FDA commissioner shifting the question from whether he will be fired to when. On the lates...
UCB is the latest biopharma player to consummate a multibillion-dollar deal amid a surge in biotech M&A activity, acquiring Ken Song’s Candid Therapeutics, one of the leading T cell engager companies. On the latest BioCe...
More than 175 new oncology targets surfaced at this year’s American Association for Cancer Research annual meeting in San Diego, with the focus on new ways to enhance the immune response against solid tumors and to make ...
Bispecific antibodies and dual-payload antibody-drug conjugates were in the spotlight at this year’s American Association for Cancer Research meeting in San Diego as biotechs unveiled their latest preclinical and first-i...
The past week has delivered the largest M&A deal ever for a private, venture-backed biopharma, the second-largest follow-on ever for a NASDAQ-traded biotech and what could soon become the largest biotech IPO ever on NASD...
A pathway proposed by FDA to cut the time it takes biopharma companies to get to first-in-human trials is more ambitious than similar policies in Australia, China and the U.K. On the latest BioCentury This Week podcast, ...
Biotech has been resilient as the financial markets teeter under global volatility. For now, M&A and financings, if not IPOs, are continuing, but will the Mideast conflict halt biotech’s recovery? On the latest BioCentur...
Biotech innovators around the world are finding speed to be the driver for investment and partnering — speed to early human data and speed to de-risk assets. The new momentum from Asia, in particular China, has added a f...
A flurry of deals, several with sizable upfront payments, has energized the biotech sector in March. On the latest BioCentury This Week podcast, BioCentury’s Paul Bonanos assesses last week’s deals by Merck, which is lay...
After 20 years of platform building and resets, Arrowhead Pharmaceuticals is making a bid to become a large-cap biotech. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss how the company has built...
Biotechs have been pricing follow-ons at a steady pace, with some companies parlaying data into upsized deals, and others even beginning to debut on NASDAQ — but will geopolitical tensions and war in the Middle East scut...
Remplissez le formulaire ci-dessous. Veillez à sélectionner à la fois Pays et Genres.
Envoyez-nous un message ci-dessous. Nous vous répondrons dans les 24 heures.